Cargando…
PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer
The discovery of prostate-specific antigen (PSA) as a biomarker represented a major discovery in the early diagnosis and monitoring of prostate cancer. However, the use of PSA is limited by the lack of specificity and an inability to differentiate indolent from life-threatening disease reliably at t...
Autores principales: | Tosoian, Jeffrey, Loeb, Stacy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
TheScientificWorldJOURNAL
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763794/ https://www.ncbi.nlm.nih.gov/pubmed/20890581 http://dx.doi.org/10.1100/tsw.2010.182 |
Ejemplares similares
-
Biomarkers in active surveillance
por: Loeb, Stacy, et al.
Publicado: (2018) -
Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening
por: Alam, Ridwan, et al.
Publicado: (2017) -
Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions
por: Eyrich, Nicholas W., et al.
Publicado: (2021) -
Beyond PSA: The Role of Prostate Health Index (phi)
por: Ferro, Matteo, et al.
Publicado: (2020) -
Particle therapy for prostate cancer: The past, present and future
por: Ishikawa, Hitoshi, et al.
Publicado: (2019)